Therapeutics News and Research

RSS

Adaptimmune initiates Phase I/IIa open-label clinical trial in patients with ovarian cancer

Adaptimmune announced today that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer at Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., and City of Hope (COH) in Duarte, Calif.

26 Jul 2013

Enzyme in airway lining cells could hold key for asthma sufferers

An enzyme known for its role in heart disease may well be a promising target to treat asthma. Researchers from the University of Iowa have found that the enzyme, called CaMKII, is linked to the harmful effects of oxidation in the respiratory tract, triggering asthmatic symptoms.

25 Jul 2013

UL researcher receives €1.5 million to develop innovative treatments for bone-loss diseases

UL researcher, Dr David Hoey was announced as one of the recipients of the highly prestigious European Research Council (ERC) starting grants. Dr Hoey has been awarded €1.5 million to pursue cutting-edge fundamental research into developing innovative treatments for bone-loss diseases such as osteoporosis. Every 30 seconds a person suffers an osteoporosis-related hip fracture in the EU.

24 Jul 2013

Researchers discover mechanism that prevents immune system from spinning out of control

A team led by a University of Arizona researcher has discovered a previously unknown mechanism that prevents the immune system from going into overdrive, shedding light not only on how our body controls its response to pathogens but on conditions such as autoimmune diseases, allergies and chronic inflammation as well.

24 Jul 2013

p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

P53 is a tumor suppressor gene. The gene encodes for a protein that monitors the state of the cell. If something goes wrong, it stops the cell from dividing or causes the cell to commit suicide. I call it the “guardian of the genome” as it is the molecule that seems to keep cells normal. It is one of our big defenses against cancer.

22 Jul 2013

GW Pharmaceuticals to expand marketing authorization for Sativex to France

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that it has submitted an application under the European Mutual Recognition Procedure seeking to expand the marketing authorization for Sativex into France for the treatment of spasticity due to Multiple Sclerosis.

22 Jul 2013

Drug release of tramadol hydrochloride increases from 1.9 to 7.5 hours by adding Novozymes Biopharma’s Hyasis®

Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.

22 Jul 2013

Implications for treating some common food allergies

Food is an integral part of life; but, for some, it can be harmful. Allergic inflammation caused by inappropriate immune responses to some types of food has become a major public health issue. Over the past ten years, the prevalence of food allergies has increased by nearly 20 percent, affecting an estimated six million people in the U.S.

22 Jul 2013

New data identifies specific cellular pathways by which RNS60 impacts Alzheimer's Disease

On Wednesday Revalesio Corporation presented new data at the Alzheimer's Association International Conference that identifies the specific cellular pathways by which Revalesio's lead investigational product, RNS60, impacts Alzheimer's Disease. This research, conducted in partnership with Rush University Medical Center, investigates a new category of therapeutics using Revalesio's novel nanotechnology platform.

19 Jul 2013

NGM Biopharmaceuticals announces completion of $50 million Series C financing

NGM Biopharmaceuticals, Inc. announced today the successful completion of a $50 million Series C financing to support advancing its portfolio of potential therapeutics for the treatment of diabetes, obesity and other cardio-metabolic diseases.

19 Jul 2013

Ensemble Therapeutics announces initiation of drug discovery collaboration with Alexion subsidiary

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the potential to modulate targets typically addressed by biologics, today announced the initiation of a drug discovery collaboration with a subsidiary of Alexion Pharmaceuticals, Inc., the global biopharmaceutical company focused on developing and commercializing life-transforming therapies for patients with life-threatening, ultra-rare disorders.

18 Jul 2013

Audentes Therapeutics closes $30 million Series A financing

Audentes Therapeutics, Inc., a recently founded biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, today announced the closing of a $30 million Series A financing.

18 Jul 2013

CHOP-led research increases numbers of patients who could be treated with gene therapy

Gene therapy researchers have produced a bioengineered decoy that fools the immune system and prevents it from mistakenly defeating the benefits delivered by a corrective gene.

18 Jul 2013

Transition Therapeutics' ELND005 receives Fast Track Designation from FDA

Transition Therapeutics Inc. announced that the US Food and Drug Administration has granted Fast Track Designation to the development program for ELND005 which was submitted for the treatment of Neuropsychiatric Symptoms in Alzheimer's disease.

18 Jul 2013

Discovery provides evidence that genetic defect responsible for Down syndrome can be suppressed

Scientists at the University of Massachusetts Medical School are the first to establish that a naturally occurring X chromosome "off switch" can be rerouted to neutralize the extra chromosome responsible for trisomy 21, also known as Down syndrome, a genetic disorder characterized by cognitive impairment.

18 Jul 2013

Drug that spurs cancer cells to self-destruct is on road to human clinical trials

Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials. The compound, known as PAC-1, has so far proven safe and has promising anti-cancer effects in cell culture, in mouse models of cancer and in pet dogs with spontaneously occurring lymphomas and osteosarcomas.

18 Jul 2013

Chemical compound from ocean microbe offers potential treatments for anthrax

A team led by William Fenical at Scripps Institution of Oceanography at UC San Diego has discovered a new chemical compound from an ocean microbe in a preliminary research finding that could one day set the stage for new treatments for anthrax and other ailments such as methicillin-resistant Staphylococcus aureus (MRSA).

18 Jul 2013

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the U.S. Food and Drug Administration has granted Fast Track designation to AYX1 Injection for the prevention of chronic pain.

17 Jul 2013

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.

17 Jul 2013

Protein complex may be an effective alternative to opioid pain medications

A drug targeting a protein complex containing two different types of opioid receptors may be an effective alternative to morphine and other opioid pain medications, without any of the side effects or risk of dependence, according to research led by the Icahn School of Medicine at Mount Sinai.

16 Jul 2013

Therapeutics News and Research

Adaptimmune initiates Phase I/IIa open-label clinical trial in patients with ovarian cancer

Enzyme in airway lining cells could hold key for asthma sufferers

UL researcher receives €1.5 million to develop innovative treatments for bone-loss diseases

Researchers discover mechanism that prevents immune system from spinning out of control

p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

GW Pharmaceuticals to expand marketing authorization for Sativex to France

Drug release of tramadol hydrochloride increases from 1.9 to 7.5 hours by adding Novozymes Biopharma’s Hyasis®

Implications for treating some common food allergies

New data identifies specific cellular pathways by which RNS60 impacts Alzheimer's Disease

NGM Biopharmaceuticals announces completion of $50 million Series C financing

Ensemble Therapeutics announces initiation of drug discovery collaboration with Alexion subsidiary

Audentes Therapeutics closes $30 million Series A financing

CHOP-led research increases numbers of patients who could be treated with gene therapy

Transition Therapeutics' ELND005 receives Fast Track Designation from FDA

Discovery provides evidence that genetic defect responsible for Down syndrome can be suppressed

Drug that spurs cancer cells to self-destruct is on road to human clinical trials

Chemical compound from ocean microbe offers potential treatments for anthrax

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Protein complex may be an effective alternative to opioid pain medications

Industry Focus eBook - Microbiome (1st edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News